Hospital Universitario Virgen de las Nieves-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2021

  1. Copy neutral loh affecting the entire chromosome 6 is a frequent mechanism of hla class i alterations in cancer

    Cancers, Vol. 13, Núm. 20

  2. The current role of the heavy/light chain assay in the diagnosis, prognosis and monitoring of multiple myeloma: An evidence-based approach

    Diagnostics, Vol. 11, Núm. 11

2019

  1. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer

    Annals of Surgical Oncology, Vol. 26, Núm. 8, pp. 2631-2639

2018

  1. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15

    Immunogenetics, Vol. 70, Núm. 10, pp. 647-659

2016

  1. Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients

    American Journal of Hematology, Vol. 91, Núm. 7, pp. 700-704

2015

  1. Trends in survival of multiple myeloma: A thirty-year population-based study in a single institution

    Cancer Epidemiology, Vol. 39, Núm. 5, pp. 693-699

2008

  1. Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines

    Cancer Immunology, Immunotherapy, Vol. 57, Núm. 5, pp. 719-729

2007

  1. Different mechanisms can lead to the same altered HLA class I phenotype in tumors

    Tissue Antigens

  2. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines

    BMC Cancer, Vol. 7

  3. Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy

    Cancer Immunology, Immunotherapy

  4. Patterns of constitutive and IFN-γ inducible expression of HLA class II molecules in human melanoma cell lines

    Immunogenetics, Vol. 59, Núm. 2, pp. 123-133

2005

  1. High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity

    Cancer Immunology, Immunotherapy, Vol. 54, Núm. 2, pp. 141-148